IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC
Thymoma
Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Thymoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Avelumab National Cancer Institute (NCI) | Phase 2 | CCC |
Bosutinib Nagla Abdel Karim | Phase 1 | CC |
Palifosfamide-Tris Alaunos Therapeutics | Phase 1 | CC |
Doxepin Mayo Clinic | Phase 2 | C |
Same molecule, other indications
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →